Multinational pharmaceutical companies are finding it difficult to enter Saudi Arabia, according to a study by Decisions Resources, which cited the nation’s strict policies for registration, pricing and drug distribution as major factors. Meanwhile, the Saudi government has implemented policies to encourage growth of the domestic pharmaceuticals industry, an Alpen Capital report found. Business Monitor International places Saudi Arabia as the largest pharmaceutical market in the Gulf Cooperation Council, where health care spending is projected to triple to $133.19 billion by 2018.

Related Summaries